Kumar, S K <br/><br/>
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.  [electronic resource] 

 -  Leukemia  Apr 2016 
 - 995-8 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2015.225  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Bortezomib--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Follow-Up Studies<br/>Health Care Costs--statistics & numerical data<br/>Health Resources--statistics & numerical data<br/>Humans<br/>Lenalidomide<br/>Multiple Myeloma--diagnosis<br/>Neoplasm Staging<br/>Prognosis<br/>Survival Rate<br/>Thalidomide--administration & dosage